Table 3 Calibration of 3-year and 5-year OS by the nomogram-revised risk index.

From: Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making

NRI defined

t (year)

Estimation by Kaplan–Meier method

Predicted OS in validation cohort

Observed OS in derivation cohort

Observed OS in validation cohort

Risk group

No.

Ev.

S (t)

SE

No.

Ev.

S (t)

SE

\(\overline {\mathit{S}}\)(t)

Low risk

3

298

39

0.878

0.021

352

40

0.896

0.018

0.892

5

0.866

0.022

0.854

0.023

0.859

Intermediate low risk

3

471

140

0.751

0.022

447

75

0.820

0.020

0.823

5

0.664

0.026

0.787

0.024

0.767

Intermediate high risk

3

367

161

0.592

0.028

423

113

0.716

0.024

0.701

5

0.486

0.031

0.684

0.027

0.628

High risk

3

162

83

0.475

0.043

223

85

0.548

0.038

0.539

5

0.408

0.045

0.525

0.040

0.442

Very high risk

3

85

63

0.272

0.055

137

79

0.351

0.048

0.349

5

0.212

0.053

0.332

0.049

0.242

  1. OS overall survival, NRI nomogram-revised risk index, t follow-up time, Ev. number of events, S (t) observed overall survival probabilities at the follow-up time, SE standard error, \(\overline {\mathit{S}}\) (t) predictive overall survival probabilities from the derivation cohort by applying the nomogram-revised risk index to the baseline survival estimate at the individual level in the validation cohort, and averaging across each risk group.